cells

Lung Cancer Clinical Trials

Non-Small Cell Lung Cancer, PD-L1 Positive (ARC-7)

Overview

A Phase 2 randomized, open-label trial to evaluate the safety and efficacy of zimberelimab monotherapy, domvanalimab in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant in front-line non-small cell lung cancer.

Key Eligibility Criteria

  • Histologically confirmed squamous or nonsquamous, PD-L1 positive, non-small cell lung cancer that is metastatic
  • No sensitizing EGFR or ALK mutation expression

ARC-7 Clinical Trial Locations

clinicaltrials.gov

arrow

Non-Small Cell Lung Cancer, PD-L1 Positive (ARC-10)

Overview

A randomized Phase 3, open-label, study to evaluate the efficacy of zimberelimab (AB122) monotherapy compared to standard chemotherapy or zimberelimab combined with domvanalimab (AB154) in front-line, PD-L1-positive locally advanced or metastatic non-small cell lung cancer.

Key Eligibility Criteria

  • Histologically confirmed, squamous or nonsquamous, treatment-naive PD-L1 positive, NSCLC that is locally advanced or metastatic without sensitizing epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation
  • Naive to any prior treatment with immune checkpoint blockade therapy

ARC-10 Clinical Trial Locations

clinicaltrials.gov

arrow

Unresectable, Stage III, Non-Small Cell Lung Cancer (PACIFIC-8)

Overview

A Phase 3, randomized, double-blind, placebo-controlled, multicenter, international study of durvalumab plus domvanalimab in participants with locally advanced (Stage III), unresectable non-small cell lung cancer whose disease has not progressed following definitive platinum-based concurrent chemoradiation therapy (CRT).

Key Eligibility Criteria

  • Histologically- or cytologically-documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease
  • Provision of a tumor tissue sample obtained prior to CRT
  • Documented tumor PD-L1 status ≥ 1% by central lab
  • Documented EGFR and ALK wild-type status (local or central)
  • Patients must not have progressed following definitive, platinum-based, concurrent chemoradiotherapy

PACIFIC-8 Clinical Trial Locations

clinicaltrials.gov

arrow

Metastatic Non-Small Cell Lung Cancer (STAR-121)

Overview

A randomized Phase 3 open-label study comparing domvanalimab and zimberelimab in combination with chemotherapy versus pembrolizumab with chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer.

Key Eligibility Criteria

  • Life expectancy ≥ 3 months
  • Pathologically documented Stage IV NSCLC with negative results for EGFR and ALK mutations and no known genomic alterations in ROS1, NTRK, BRAF, RET or other actionable driver oncogenes
  • Have not received prior systemic treatment for metastatic NSCLC
  • Does not have mixed small-cell lung cancer (SCLC) and NSCLC histology

STAR-121 Clinical Trial Locations

clinicaltrials.gov

arrow